Retatrutide (LY3437943, also referred to informally as "reta peptide") is a synthetic 39-amino-acid peptide developed by Eli Lilly that acts simultaneously on three distinct metabolic receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and the glucagon receptor
Your provider will be able to monitor your weight loss and determine if you are a candidate for GLP-1s, and whether microdosing could be effective for you
When someone is getting a subcutaneous injection, it simply means the medication is being injected into the third layer, the subcutaneous layer, and not deeper into the muscle
Ozempic face is caused by rapid volume loss in both the superficial and deep fat pads of the face, as well as changes in skin barrier function, Moschitto continues, The superficial fat pads provide direct structural support to the skin
Patients should seek immediate evaluation for symptoms such as difficulty breathing, facial or throat swelling, widespread rash, or significant skin changes that go beyond a typical injection site reaction
doi: 10.1016/j.intimp.2019.105969 28 HelmstdterJKeppelerKAustFKsterLFrenisKFilippouKet al